Results from BREAKWATER Cohort 3 trial show clinically meaningful improvements in objective response rate and progression-free survival for encorafenib, cetuximab plus FOLFIRI in BRAF V600E-mutant colorectal cancer
fondazionebonadonna.org/en/encorafen...
#FondazioneBonadonna #CancerResearch
